ls"The Museum of Bioprospecting, Intellectual Property, and the Public Domainrs" addresses one of the most heated policy debates of our day: access to genetic resources and the fair and equitable sharing of benefits. Seven scholars an anthropologist, an economist, a sociologist, and four lawyers discuss how a museum can flesh out the relevant ethical issues that frustrate any purely technical solution. The visitors to the proposed museum become a source of considered judgments. Commercial movies are screened and discussion follows about some aspect of bioprospecting, intellectual property, and the public domain, suggested in the films. Both the screenings and discussions occur in small amphitheatres named according to the uneven chronology in the management of information: 100,00 BC to 16 September 1787 (public domain); 17 September 1787 to todayrs"s date (intellectual property); and todayrs"s date to (?) (legislation sui generis). The three amphitheatres surround a courtyard cafeacute; which is a metaphor for the mission of the museum: conversation. The scholars vet the blueprint before an imaginary octogenarian who is not at all impressed and will "say the damnedest things." As this 21st century Don Quixote moseys across the chapters and pokes fun at the scholarly ruminations, the reader begins to understand how the proposed museum is indeed a forum for the nuanced ethics over bioprospecting, intellectual property, and the public domain. The dialogue-within-a-dialogue is highly original and entertaining.
Principles; Migration in the space-time & frequency domain; Optimised & non-linear migration; Effect of velocity structure inhomogeneity; Pseudo-three-dimensional & three-dimensional migrations; Peculiarities of migration results & technology.
The access and benefit-sharing (ABS) policy process of the Convention on Biological Diversity (CBD), and wider discussions about the ethical and conservation issues arising from the commercial use of biodiversity and traditional knowledge, depend upon a well-developed understanding of the activities known broadly as 'bioprospecting'. However, the pace at which our understanding of genetic and other biological resources is accelerating, and market and industry trends are also undergoing constant change.
This book provides information and insights into current practices and trends in biodiversity research and bioprospecting, including for potential medicines, food and cosmetics. It presents background information on markets, research and development, and explores recent extraordinary developments in science and technology and their implications for ABS policy development and implementation. The authors present a brief history of the commercial use of biodiversity, and review key trends across sectors. The book continues with chapters devoted to the main industry sectors, including pharmaceuticals and healthcare, agriculture, industrial process biotechnology and food and beverages. Each chapter includes explanatory boxes to describe key technologies and concepts which are less widely understood, as well as input from various stakeholders including industry representatives, NGOs and researchers. It concludes with a review of industry awareness of and engagement with the CBD, ABS and other policy processes. It is an invaluable resource for all concerned with commercial bioprospecting and the implementation of ABS laws and regulations, particularly in light of the adoption of the Nagoya Protocol.
Discover Metals Articles
Discover Metals Books